Kinnov Therapeutics Completes Successful Phase 2 study for Alcohol Use Disorder

Sage’s new client, Kinnov Therapeutics, is a French-based company focused on one of the major unmet global healthcare challenges, addiction. Kinnov has engaged the Sage Group to manage its sale process. On this site, under our listed Kinnov profile, is a nonconfidential presentation on Kinnov’s product, KT-110, for Alcohol Use Disorder (AUD) for which there has been no new treatment in nearly a decade. KT-110 is a game changer in AUD treatment with blockbuster potential. It has completed a Phase 2 clinical study with excellent results.

KT-110, a convenient once-daily tablet, is a new, innovative dual-action formulation combining prazosin and cyproheptadine which together have a potent synergistic effect on addiction. As such, it is a First-in-Class product addressing a worldwide market of over 200 million individuals (only 10% of which receive any treatment whatsoever and even fewer are treated pharmacologically) costing global healthcare systems hundreds of billions of dollars and the lives of over 3 million people each year. KT-110 is protected by increasingly strong patents in addition to data protection regulations in the U.S and Europe.

In a Phase 2 Proof-of-Concept (PoC) study, KT-110, achieved a consistent effect on all meaningful Alcohol Use Disorder (AUD) parameters